Investor Presentation: First Nine Months of 2020
9
Investor presentation
First nine months of 2020
Promising RybelsusⓇ launch in the US with European launches
underway
Launch uptake of Rybelsus® vs SGLT-2s 1 in the US
RybelsusⓇ re-gaining momentum in the US
and launches in Europe are underway
NBRX count
4,500
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
0
Rybelsus
SGLT-2s
In the US:
к
•
•
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52
Weeks
1 SGLT-2s is an average of empagliflozin and canagliflozin NBRx count.
Source: IQVIA Xponent, weekly, Oct 2020
NBRX: New-to-brand prescriptions
Market access now around 85% across commercial and
Medicare
More than 80% of new prescriptions are new to the GLP-1 class
Direct-to-consumer advertising initiated 21 September 2020
Outside of the US, RybelsusⓇ has now been launched in eight
countries
Novo Nordisk®View entire presentation